Overview - ISO 23033:2021 (Biotechnology, Analytical Methods)
ISO 23033:2021 provides general requirements and practical considerations for the testing and characterization of cellular therapeutic products intended for human use. The standard guides the selection and design of fit‑for‑purpose analytical methods used across development, manufacturing and release testing - from cellular starting materials and intermediates (including tissue‑engineered product inputs) through final product testing. It is explicit that the document is not applicable to tissues used in transplantation.
Key topics and technical requirements
- Design of analytical methods: principles for developing methods that meet an Analytical Target Profile (ATP) and are appropriate for the biological complexity of cell‑based products.
- Matrix approach: selecting complementary methods to evaluate multiple quality attributes (identity, potency, purity, viability, cell count, stability).
- Quality attributes and CQAs: guidance on establishing Critical Quality Attributes (CQAs) and linking them to the measurement strategy.
- Method performance and lifecycle: qualification, validation and continued verification of analytical methods; setting test method performance criteria.
- Instrument selection and qualification: criteria for choosing instruments, and requirements for instrument qualification and maintenance.
- Sources of variability: identifying and managing variability from sampling, sample preparation, reference materials, reagents and biological heterogeneity.
- Specific testing considerations: approaches for assessing identity, cell count, viability, potency (including assay design and importance as a CQA), microbiological contamination, purity and stability.
- Documentation and reporting: requirements for procedure documentation and reporting test results to support release, stability and comparability decisions.
Practical applications - who uses ISO 23033:2021
This standard is used by organizations involved in the development, manufacture and regulation of cellular therapies:
- Biotechnology and cell therapy developers designing analytical strategies and CQAs.
- QC/QA laboratories validating and maintaining cell‑based assays (identity, potency, viability, sterility).
- Contract testing organizations and CROs performing release and stability testing.
- Regulatory affairs and manufacturing teams preparing dossiers or comparability studies.
- Instrument vendors and method developers aligning products and assays with fit‑for‑purpose expectations.
Practical benefits include improved assay robustness, clearer release criteria, better management of measurement variability, and a defensible analytical strategy for product development and regulatory submissions.
Related standards
- ISO/TS 20399‑1:2018 (referenced in ISO 23033 definitions) - guidance on ancillary materials and related terminology.
- ISO/TC 276 (Biotechnology) provides the broader technical committee context for cell therapy standards.
Keywords: ISO 23033:2021, cellular therapeutic products, analytical methods, critical quality attributes, potency assay, cell count, viability, analytical method validation, fit for purpose, instrument qualification, testing strategy.